Q-SPECT/CT 在 COVID-19 合并中高验前概率肺栓塞诊断中的临床价值
该研究回顾性分析 2020 年 3 月至 6 月在纪念斯隆-凯特琳癌症中心连续收治的 COVID-19 患者,采用仅灌注(Q)SPECT/CT 诊断肺栓塞。6 例实验室确诊 COVID-19 且均有恶性肿瘤、验前概率中高(平均 Wells 评分 2.8,范围 2-4)的患者中,Q-SPECT/CT 阳性 4/6(67%),栓塞分布以双侧段性为主(75%)。结论认为 Q-SPECT/CT 对存在碘对比剂禁忌且验前概率中高的 COVID-19 患者诊断 PE 具有临床效用。
要点
- Q-SPECT/CT 在 6 例 COVID-19 合并恶性肿瘤患者中诊断 PE 阳性率为 67%(4/6)。
- 阳性患者中 75% 表现为双侧段性肺栓塞分布。
- 适用于碘对比剂禁忌且验前概率中高的 COVID-19 疑似 PE 患者。
核心结论
- Q-SPECT/CT 对存在碘对比剂禁忌且验前概率中高的 COVID-19 患者诊断 PE 具有临床效用。
研究设计与样本
- 回顾性综述 2020 年 3 月 17 日至 6 月 30 日在纪念斯隆-凯特琳癌症中心连续收治的 COVID-19 患者,均接受 Q-SPECT/CT 检查。
- 共 33 例患者接受 Q-SPECT/CT 成像,其中 6 例实验室确诊 COVID-19(3 男 3 女,平均年龄 55±11.4 岁,范围 33-68 岁)。
- 所有 6 例患者均有恶性肿瘤诊断,且 PE 验前概率为中或高(平均 Wells 评分 2.8,范围 2-4)。
主要发现
- Q-SPECT/CT 在 4/6(67%)的患者中为阳性。
- 肺栓塞分布为双侧且段性者占 75%。
- SPECT/CT 辅助急性发现包括双侧肺实质磨玻璃影(n=5)、胸腔积液(n=2)和纵隔气肿(n=1)。
临床怎么用
- 对于 COVID-19 患者,当存在碘对比剂禁忌且 PE 验前概率为中或高时,可考虑使用 Q-SPECT/CT 诊断 PE。
局限性
- 研究为单中心回顾性综述,最终分析仅纳入 6 例实验室确诊 COVID-19 患者,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We reviewed the clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). METHODS: Following the World Health Organization's declaration of a global pandemic, our department policy recommended Q-only SPECT/CT for all patients undergoing nuclear medicine evaluation for suspected PE to reduce the risk of aerosolization of respiratory droplets. We performed a retrospective review of sequential patients admitted with COVID-19 imaged with Q-SPECT/CT between March 17, 2020, and June 30, 2020, at Memorial Sloan Kettering Cancer Center. We recorded patient demographics, clinical symptoms, Wells score (to stratify patients according to pre-test probability for PE prior to Q-SPECT/CT), and noted ancillary imaging findings on CT. RESULTS: Of the 33 patients imaged with Q-SPECT/CT, 6 patients (3 men, 3 women) had a laboratory confirmed diagnosis of COVID-19 (mean age, 55, ± 11.4 years, range 33-68). All patients had a current diagnosis of malignancy and had a moderate or high pre-test probability for PE (mean Wells score 2.8, range 2-4). Q-SPECT/CT was positive in 4/6 (67%) of patients. Distribution of pulmonary emboli was bilateral and segmental in 75% of patients. Ancillary acute findings on SPECT/CT included bilateral parenchymal ground glass opacities (n = 5), pleural effusions (n = 2), and pneumomediastinum (n = 1). CONCLUSION: Q-SPECT/CT has clinical utility for diagnosing PE in patients with COVID-19 where there is a contraindication for iodinated contrast media and a moderate or high pre-test probability for PE.
引用
- Das JP, Yeh R, Schöder H, et al. Clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in COVID-19 patients with a moderate to high pre-test probability of PE. Eur J Nucl Med Mol Imaging. 2020. PMID: 32959115. doi:10.1007/s00259-020-05043-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。